Biggest COVID-19 trial tests repurposed drugs first

  title={Biggest COVID-19 trial tests repurposed drugs first},
  journal={Nature Biotechnology},
  • Published 2020
  • Medicine
  • Nature Biotechnology
for patients, M2-like TAMs typically predominate in most tumors. Aiming to reprogram those TAMs, more than two dozen companies are now developing drugs directed against the CD47 axis. The best known and most clinically advanced of these is Forty Seven, maker of a humanized IgG4 monoclonal antibody called magrolimab. This CD47-targeted therapy is slated to enter registration-enabling trials in the coming months and could reach the market as soon as 2022. In March, Gilead Sciences announced plans… Expand
8 Citations

Topics from this paper

Therapeutic approaches against coronaviruses acute respiratory syndrome